atrasentan has been researched along with Metabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ | 1 |
| Holmes, DR; Kent, B; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E | 1 |
1 trial(s) available for atrasentan and Metabolic Syndrome
| Article | Year |
|---|---|
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.
Topics: Adult; Antihypertensive Agents; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Edema; Endothelin A Receptor Antagonists; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension; Kidney; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pyrrolidines; Receptor, Endothelin A; Risk Factors; Treatment Outcome | 2008 |
1 other study(ies) available for atrasentan and Metabolic Syndrome
| Article | Year |
|---|---|
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Cell Adhesion Molecules; Chlorthalidone; Deoxyguanosine; Disease Models, Animal; Diuretics; Drug Combinations; Endothelin A Receptor Antagonists; Endothelins; Hypertension; Inflammation; Kidney Diseases; Male; Membrane Proteins; Metabolic Syndrome; Oxidative Stress; Proteinuria; Pyrrolidines; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium Chloride, Dietary | 2014 |